ReviewLipids in health and disease2016
Detection and treatment of omega-3 fatty acid deficiency in psychiatric practice: Rationale and implementation.
Review in Lipids in health and disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 53 citations in OpenAlex.
- A to Z of Health: An Evidence-Based Narrative Review of Multivitamin-Multimineral and Nutraceutical Supplementation.Cureus · 2026Review
- Omega-3 fatty acids in mental disorders: from neurobiological and metabolic mechanisms to therapeutic potential.Frontiers in nutrition · 2026Review
- Dietary changes as a risk factor and remedy for meditation-related challenges.Frontiers in nutrition · 2025Article
- Neurodevelopmental trajectories, polygenic risk, and lipometabolism in vulnerability and resilience to schizophrenia.BMC psychiatry · 2023Article
- Microbial originated surfactants with multiple applications: a comprehensive review.Archives of microbiology · 2022Review
- Tissue-Specific Content of Polyunsaturated Fatty Acids in (n-3) Deficiency State of Rats.Foods (Basel, Switzerland) · 2022Article
- Peripheral biomarkers of treatment-resistant schizophrenia: Genetic, inflammation and stress perspectives.Frontiers in pharmacology · 2022Review
- Shared Biological Pathways between Antipsychotics and Omega-3 Fatty Acids: A Key Feature for Schizophrenia Preventive Treatment?International journal of molecular sciences · 2021Review
- Article
- Review
- The Role of GPR120 Receptor in Essential Fatty Acids Metabolism in Schizophrenia.Biomedicines · 2020Article
- Ultralong TE In VivoJournal of magnetic resonance imaging : JMRI · 2019Article
- Omega-3 fatty acids supplementation with lithium and aripiprazole for improving the balance of circulating hormones and brain neurotransmitters in manic mice model.Naunyn-Schmiedeberg's archives of pharmacology · 2018Article
- Antidepressant-Induced Activation in Children and Adolescents: Risk, Recognition and Management.Current problems in pediatric and adolescent health care · 2018Review
- Food for Mood: Relevance of Nutritional Omega-3 Fatty Acids for Depression and Anxiety.Frontiers in physiology · 2018Review
- Regulatory T Cells As Supporters of Psychoimmune Resilience: Toward Immunotherapy of Major Depressive Disorder.Frontiers in neurology · 2018Article
- Docosahexaenoic Acid Reduces Cerebral Damage and Ameliorates Long-Term Cognitive Impairments Caused by Neonatal Hypoxia-Ischemia in Rats.Molecular neurobiology · 2017Article
- Emotion-Based Cognition in Mice Is Differentially Influenced by Dose and Chemical Form of Dietary Docosahexaenoic Acid.Nutrients · 2017Article
- Polyunsaturated fatty acids and recurrent mood disorders: Phenomenology, mechanisms, and clinical application.Progress in lipid research · 2017Review
- Chronic Psychological Stress Was Not Ameliorated by Omega-3 Eicosapentaenoic Acid (EPA).Frontiers in pharmacology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
A body of translational evidence has implicated dietary deficiency in long-chain omega-3 (LCn-3) fatty acids, including eicosapenaenoic acid (EPA) and docosahexaenoic acid (DHA), in the pathophysiology and potentially etiology of different psychiatric disorders. Case-control studies have consistently observed low erythrocyte (red blood cell) EPA and/or DHA levels in patients with major depressive disorder, bipolar disorder, schizophrenia, and attention deficit hyperactivity disorder. Low erythrocyte EPA + DHA biostatus can be treated with fish oil-based formulations containing preformed EPA + DHA, and extant evidence suggests that fish oil supplementation is safe and well-tolerated and may have therapeutic benefits. These and other data provide a rationale for screening for and treating LCn-3 fatty acid deficiency in patients with psychiatric illness. To this end, we have implemented a pilot program that routinely measures blood fatty acid levels in psychiatric patients entering a residential inpatient clinic. To date over 130 blood samples, primarily from patients with treatment-refractory mood or anxiety disorders, have been collected and analyzed. Our initial results indicate that the majority (75 %) of patients exhibit whole blood EPA + DHA levels at ≤ 4 percent of total fatty acid composition, a rate that is significantly higher than general population norms (25 %). In a sub-set of cases, corrective treatment with fish oil-based products has resulted in improvements in psychiatric symptoms without notable side effects. In view of the urgent need for improvements in conventional treatment algorithms, these preliminary findings provide important support for expanding this approach in routine psychiatric practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.